Enterprise Value
1.065B
Cash
776.9M
Avg Qtr Burn
-74.02M
Short % of Float
13.98%
Insider Ownership
1.62%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Approved Quarterly sales | |
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia) | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Anemia, Sickle cell disease | Phase 3 Data readout | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Pyruvate Kinase Deficiency | Phase 3 Data readout | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Beta thalessemia Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Vorasidenib (Pan-IDHm inhibitor) Details Glioma, Brain tumor | Phase 3 Update | |
AG-946 Details Myelodysplastic syndrome | Phase 2b Initiation |